drug
Kapanol
Marketedupdated 3mo agoby Teva Pharmaceuticals USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval428 co-mentions · 214 sources
- drugMS CONTIN261 co-mentions · 221 sources
- drugDURAMORPH PF245 co-mentions · 221 sources
- drugInfumorph245 co-mentions · 221 sources
- drugmorphine sulfate ER221 co-mentions · 221 sources
- drugMorphine Sulfate Pfizer221 co-mentions · 221 sources
- drugmorphine sulfate SR221 co-mentions · 221 sources
- drugMorphine Sulfate Mallinckrodt221 co-mentions · 221 sources
all catalysts(100)
approval · 100
Sep 18, 1984
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
Aug 22, 1985
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
May 29, 1987
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Apr 8, 1988
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
May 2, 1988
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
May 3, 1989
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
Sep 12, 1989
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Jan 16, 1990
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Apr 12, 1990
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Jul 19, 1991
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
Jul 19, 1991
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
Nov 8, 1993
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Apr 28, 1994
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
Feb 12, 1997
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
Apr 29, 1997
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Apr 17, 1998
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
Jun 14, 1999
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
May 2, 2000
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
May 2, 2000
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
May 2, 2000
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
May 2, 2000
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
May 2, 2000
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
May 12, 2000
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Jun 27, 2000
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Feb 12, 2001
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Dec 7, 2001
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
Dec 18, 2001
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Feb 21, 2003
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Jun 26, 2003
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
Aug 6, 2003
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
May 27, 2004
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
Jun 6, 2005
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
May 11, 2007
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Mar 17, 2008
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Mar 17, 2008
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Jan 25, 2010
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Apr 15, 2010
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
May 11, 2010
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Oct 1, 2010
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
Jun 10, 2011
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Oct 18, 2011
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Nov 10, 2011
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Nov 14, 2011
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Jan 23, 2012
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Jan 23, 2012
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Jul 9, 2012
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Jul 9, 2012
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Jan 16, 2013
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Apr 15, 2013
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Apr 15, 2013
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Apr 24, 2013
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Aug 14, 2013
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Oct 30, 2013
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Jan 9, 2014
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Apr 16, 2014
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Apr 18, 2014
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Jun 2, 2014
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Jun 23, 2014
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Jul 2, 2014
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Jul 3, 2014
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Aug 19, 2014
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Aug 19, 2014
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Aug 19, 2014
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Oct 22, 2014
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Nov 16, 2014
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Feb 6, 2015
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Mar 3, 2015
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Apr 21, 2015
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Jun 26, 2015
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Jun 26, 2015
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Jun 26, 2015
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Apr 20, 2016
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Apr 20, 2016
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Apr 20, 2016
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Jun 6, 2016
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
Sep 30, 2016
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Sep 30, 2016
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Sep 30, 2016
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Dec 16, 2016
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Dec 16, 2016
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Dec 16, 2016
approval
DURAMORPH PF (MORPHINE SULFATE) — FDA approval
Kapanol
→
Dec 16, 2016
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Dec 16, 2016
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Dec 16, 2016
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Jan 27, 2017
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
May 26, 2017
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
May 26, 2017
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
May 26, 2017
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Sep 18, 2018
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Sep 18, 2018
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Sep 18, 2018
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Sep 18, 2018
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Sep 18, 2018
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Sep 18, 2018
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Sep 18, 2018
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Sep 18, 2018
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Oct 7, 2019
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Oct 7, 2019
approval
MS CONTIN (MORPHINE SULFATE) — FDA approval
Kapanol
→
Oct 7, 2019
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Oct 7, 2019
approval
MORPHINE SULFATE — FDA approval
Kapanol
→
Trials studying Kapanol
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 19, 2027
311 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (71)
- Mar 12, 2034formulationUS 9072781
- Mar 12, 2034formulationUS 9072781
- Mar 12, 2034formulationUS 9072781
- Mar 12, 2034formulationUS 9072781
- Mar 12, 2034formulationUS 9072781
- Mar 12, 2034method-of-use (U-43)US 9192608
- Mar 12, 2034method-of-use (U-55)US 9192608
- Mar 12, 2034method-of-use (U-55)US 9192608
- Mar 12, 2034method-of-use (U-55)US 9192608
- Mar 12, 2034method-of-use (U-43)US 9192608
- Mar 12, 2034formulationUS 9248229
- Mar 12, 2034formulationUS 9248229
- Mar 12, 2034formulationUS 9248229
- Mar 12, 2034formulationUS 9248229
- Mar 12, 2034formulationUS 9248229
- Jul 1, 2033formulationUS 9044402
- Jul 1, 2033formulationUS 9044402
- Jul 1, 2033formulationUS 9044402
- Jul 1, 2033formulationUS 9549899
- Jul 1, 2033formulationUS 9549899
- Jul 1, 2033formulationUS 9549899
- Nov 7, 2029method-of-use (U-1640)US 86234183.2y
- Nov 7, 2029method-of-use (U-1640)US 86234183.2y
- Nov 7, 2029method-of-use (U-1640)US 86234183.2y
- Nov 7, 2029method-of-use (U-1640)US 86234183.2y
- Nov 7, 2029method-of-use (U-1640)US 86234183.2y
- Nov 7, 2029method-of-use (U-1640)US 86234183.2y
- Aug 12, 2028formulationUS 103147882.0y
- Aug 12, 2028formulationUS 103147882.0y
- Aug 12, 2028formulationUS 103147882.0y
- Aug 12, 2028formulationUS 103147882.0y
- Aug 12, 2028formulationUS 79556192.0y
- Aug 12, 2028formulationUS 79556192.0y
- Aug 12, 2028formulationUS 79556192.0y
- Aug 12, 2028formulationUS 79556192.0y
- Dec 12, 2027formulationUS 78159341.3y
- Dec 12, 2027formulationUS 78159341.3y
- Dec 12, 2027formulationUS 78159341.3y
- Dec 12, 2027formulationUS 78159341.3y
- Dec 12, 2027formulationUS 78159341.3y
- Dec 12, 2027formulationUS 78159341.3y
- Jun 19, 2027method-of-use (U-1510)US 7682633311d
- Jun 19, 2027method-of-use (U-1510)US 7682633311d
- Jun 19, 2027method-of-use (U-1510)US 7682633311d
- Jun 19, 2027method-of-use (U-1510)US 7682633311d
- Jun 19, 2027method-of-use (U-1510)US 7682633311d
- Jun 19, 2027method-of-use (U-1510)US 7682633311d
- Jun 19, 2027formulationUS 7682634311d
- Jun 19, 2027formulationUS 7682634311d
- Jun 19, 2027formulationUS 7682634311d
- Jun 19, 2027formulationUS 7682634311d
- Jun 19, 2027formulationUS 7682634311d
- Jun 19, 2027formulationUS 7682634311d
- Jun 19, 2027method-of-use (U-1510)US 8158156311d
- Jun 19, 2027method-of-use (U-1510)US 8158156311d
- Jun 19, 2027method-of-use (U-1510)US 8158156311d
- Jun 19, 2027method-of-use (U-1510)US 8158156311d
- Jun 19, 2027method-of-use (U-1510)US 8158156311d
- Jun 19, 2027method-of-use (U-1510)US 8158156311d
- Jun 19, 2027formulationUS 8846104311d
- Jun 19, 2027formulationUS 8846104311d
- Jun 19, 2027formulationUS 8846104311d
- Jun 19, 2027formulationUS 8846104311d
- Jun 19, 2027formulationUS 8846104311d
- Jun 19, 2027formulationUS 8846104311d
- Jun 19, 2027formulationUS 8877247311d
- Jun 19, 2027formulationUS 8877247311d
- Jun 19, 2027formulationUS 8877247311d
- Jun 19, 2027formulationUS 8877247311d
- Jun 19, 2027formulationUS 8877247311d
- Jun 19, 2027formulationUS 8877247311d
News(1)
- Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-upFOR IMMEDIATE RELEASE – 8/4/2026 – LAKE ZURICH, Ill.— Fresenius Kabi, an operating company of the Fresenius Group, is voluntarily recalling one lot of Morphine Sulfate Injection USP, Simplist® 2 mg…fda_recalls · 7d ago
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that